Methods of treating conditions using anti-IL-6 antibodies

US8067003B2 · kind B2 · utility

Assignees

• Centocor, Inc. · US
• Applied Molecular Evolution, Inc. · US

Inventors

• Yan Chen · Santa Clara, US
• Debra Gardner · Bear, US
• David Knight · Berwyn, US
• Michael W. Lark · Devon, US
• Bailin Liang · Gilbertsville, US
• David Shealy · Downingtown, US
• Xiao-yu R. Song · Bound Brook, US
• Vedrana Stojanovic-Susulic · Princeton Junction, US
• Raymond Sweet · Via Enrico Fermi, US
• Susan Tam · Boothwyn, US
• Sheng-Jiun Wu · Broomall, US
• Jing Yang · Cambridge, US
• David Matthew Marquis · Encinitas, US
• Eric Michael Smith · Galveston, US
• Alain P. Vasserot · South San Francisco, US

Key dates

• Filing date: Oct 8, 2010
• Grant date: Nov 29, 2011
• Expiry date: Oct 8, 2030

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07K2317/92
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

Anti-IL-6 antibodies are used to treat IL-6 related conditions, such as rheumatoid arthritis, osteoarthritis, osteolysis, aseptic loosening of orthopedic implants, systemic lupus erythematosus, cutaneous lupus erythematosus, lupus nephritis, type 2 diabetes mellitus, chronic obstructive pulmonary disease, and renal cell carcinoma.